MICA Mutant A5.1 Influences BK Polyomavirus Reactivation and Associated Nephropathy After Kidney Transplantation

Pierre Tonnerre1, Nathalie Gérard1, Pierre-Jean Gavlovsky1

  • 1INSERM, UMR1064, LabEx Transplantex, LabEx IGO and IHU-CESTI CHU Nantes, Institut de Transplantation et de Recherche en Transplantation-Urologie-Néphrologie, ITUN LUNAM, Université de Nantes, Faculté de Médecine.

Abstract

Insights

Major histocompatibility complex (MHC) class I-related chain A (MICA) mismatch is critical for BK polyomavirus (BKPyV) reactivation after kidney transplants. This finding may improve prevention strategies for BKPyV-associated nephropathy.

Area of Science:

  • Immunogenetics
  • Transplantation immunology
  • Virology

Background:

  • BK polyomavirus (BKPyV) reactivation is common in kidney transplant recipients, leading to nephropathy and graft loss.
  • Identifying risk factors for BKPyV reactivation is crucial for effective prevention strategies.

Purpose of the Study:

  • To investigate the role of major histocompatibility complex (MHC) class I-related chain A (MICA) in BKPyV reactivation.
  • To determine if MICA genotype and donor-recipient mismatch influence BKPyV reactivation and outcomes.

Main Methods:

  • Analysis of 144 kidney transplant donor/recipient pairs.
  • Assessment of BKPyV reactivation levels (controllers, virurics, viremic).
  • Genotyping for MICA, including the A5.1 variant, and analysis of anti-MICA sensitization and soluble MICA levels.

Main Results:

  • MICA is expressed in kidney tubule epithelial cells, the primary targets of BKPyV.
  • Recipients with a donor carrying the MICA A5.1 mutant showed lower BKPyV reactivation rates.
  • MICA A5.1 mismatch between donor and recipient was critical for BKPyV reactivation and nephropathy.
  • Low BKPyV reactivation correlated with elevated anti-MICA sensitization and reduced soluble MICA.

Conclusions:

  • MICA acts as an immunogenetic factor influencing anti-BKPyV immune responses.
  • MICA A5.1 mismatch is a significant risk factor for BKPyV reactivation and associated nephropathy.
  • These findings may inform strategies to prevent BKPyV reactivation in kidney transplant recipients.